Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alaunos Therapeutics, Inc.TCRT · Entity 8339 | Director · Chief Executive Officer | September 01, 2023 | September 05, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alaunos Therapeutics, Inc.
Report date September 01, 2023 · Filed September 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 798,236 |
Reported balance
After 2023-09-01 transaction · row 1
1 source rowRow 1 · 2023-09-01 · Sale · Disposed 68,014 · Balance 798,236 F1: Represents the sale of shares of Common Stock pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of shares of restricted stock previously granted to the Reporting Person. This sale was effected pursuant to a plan adopted on November 17, 2022 in accordance with Rule 10b5-1 and does not represent a discretionary sale by the reporting person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.14 to $0.1424, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the sale of shares of Common Stock pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of shares of restricted stock previously granted to the Reporting Person. This sale was effected pursuant to a plan adopted on November 17, 2022 in accordance with Rule 10b5-1 and does not represent a discretionary sale by the reporting person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.14 to $0.1424, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2023 Filed Sep 5, 2023 21:34 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | SaleCommon Stock | 68,014 | $0.14 | $9,542.36 |
DisclosureSEC source: 0000950170-23-046504 · ownership.xml · nonDerivative · entry 1 Boyle Kevin S. Sr. · CIK 0001880600 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 798,236 F1 · shares: Represents the sale of shares of Common Stock pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of shares of restricted stock previously granted to the Reporting Person. This sale was effected pursuant to a plan adopted on November 17, 2022 in accordance with Rule 10b5-1 and does not represent a discretionary sale by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.14 to $0.1424, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 15, 2023 Filed Mar 18, 2023 00:30 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantEmployee Stock Option (right to buy) · Derivative | 1,800,000 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0000899243-23-009000 · doc4.xml · derivative · entry 1 Boyle Kevin S. Sr. · CIK 0001880600 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,800,000 Underlying: Common Stock · 1,800,000 shares Expires 2033-03-14 F1 · derivative.exercise_date: One-sixteenth of the shares underlying the option vest in equal quarterly installments measured from January 1, 2023, with the first vesting occuring on April 1, 2023, subject to the Reporting Person's continued service through each such date. Read SEC document |
| August 30, 2022 Filed Sep 1, 2022 20:30 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | Tax withholdingCommon Stock | 18,750 | $2.41 | $45,187.50 |
DisclosureSEC source: 0000899243-22-030186 · doc4.xml · nonDerivative · entry 1 Boyle Kevin S. Sr. · CIK 0001880600 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 866,250 F1 · shares: Represents shares withheld by the Issuer to satisfy a portion of the tax withholding obligations in connection with the vesting of shares of restricted stock previously granted to the Reporting Person. Read SEC document |
| March 30, 2022 Filed Apr 1, 2022 20:30 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantEmployee Stock Option (right to buy) · Derivative | 2,000,000 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0000899243-22-013119 · doc4.xml · derivative · entry 1 Boyle Kevin S. Sr. · CIK 0001880600 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000,000 Underlying: Common Stock · 2,000,000 shares Expires 2032-03-29 F1 · derivative.exercise_date: One-sixteenth of the shares underlying the option vest in equal quarterly installments commencing three months after January 1, 2022, subject to the Reporting Person's continued service through each such date. Read SEC document |
| November 17, 2021 Filed Nov 17, 2021 21:53 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | PurchaseCommon Stock | 9,116 | $1.40 | $12,762.40 |
DisclosureSEC source: 0001209191-21-065138 · doc4.xml · nonDerivative · entry 2 Boyle Kevin S. Sr. · CIK 0001880600 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 885,000 Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 21:53 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | PurchaseCommon Stock | 884 | $1.40 | $1,237.60 |
DisclosureSEC source: 0001209191-21-065138 · doc4.xml · nonDerivative · entry 1 Boyle Kevin S. Sr. · CIK 0001880600 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 875,884 Read SEC document |
| August 30, 2021 Filed Aug 31, 2021 20:42 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantEmployee Stock Option (right to buy) · Derivative | 2,625,000 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001209191-21-054089 · doc4.xml · derivative · entry 2 Boyle Kevin S. Sr. · CIK 0001880600 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,625,000 Underlying: Common Stock · 2,625,000 shares Expires 2031-08-29 F2 · derivative.exercise_date: One-sixteenth of the shares underlying the option vest in equal quarterly installments commencing three month after 8/30/2021, subject to the Reporting Person's continued service through each such date. Read SEC document |
| August 30, 2021 Filed Aug 31, 2021 20:42 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantCommon Stock | 875,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-054089 · doc4.xml · nonDerivative · entry 1 Boyle Kevin S. Sr. · CIK 0001880600 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 875,000 F1 · shares: One-fourth of the shares vest on each of August 30, 2022, August 30, 2023, August 30, 2024 and August 30, 2025, subject to the Reporting Person's continued service through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.